A Viewpoint article published recently in the Journal of the American Medical Association suggests that the clinical practice of prescribing amphetamines, opioids, and benzodiazepines to treat chronic pain may be contributing to the increase in fatal drug overdoses and the likelihood that those drugs will be diverted to the illegal market. "Rethinking Opioid Prescribing to Protect Patient Safety and Public Health" was authored by Johns Hopkins Bloomberg School of Public Health researchers G. Caleb Alexander, MD, MS, and Daniel Webster, ScD, MPH, and Stefan P. Kruszewski, MD, of MD & Associates.
"More people in the U.S. die from a drug overdose than they do from motor vehicle accidents and more of those deaths are caused by prescription opioids than those attributable to cocaine and heroin combined," said Alexander, associate professor of Epidemiology at the Bloomberg School and co-director of the new Johns Hopkins Center for Drug Safety and Effectiveness.
There are measures currently in place to monitor the increasing epidemic of opioid abuse, including limits on the number of opioid prescriptions covered by insurers, requirements that these drugs be supplied through a single physician or pharmacy, and state prescription drug monitoring programs. However, the Viewpoint conveys that unless there is a clinical shift in the widespread use of these medicines, efforts to reduce opioid abuse may not succeed.
"Prescribing opioids as a matter of course for treatment impedes the opportunity to explore and implement other methods of therapy that could offer relief for millions of Americans who suffer from acute or chronic pain," said Webster, professor of Health Policy and Management at the Bloomberg School. "It also increases the odds these drugs will be misused or diverted from the legal to the illegal market, leading to more addiction and death."
The article reveals there are clear correlations between national trends for prescription opioid sales, admissions for substance abuse treatment, and deaths. It also recommends that existing regulatory and enforcement measures to prevent nonmedical use and diversion should be complimented by changes to clinical guidelines to treat chronic pain that are less reliant on opioids.
"It's evident more research needs to be done to identify alternative approaches to pain management and treatment, but prescribing practices must change to reverse what has become a pervasive epidemic leading to widespread morbidity, mortality, and community strife," Alexander added.
Johns Hopkins University Bloomberg School of Public Health: http://www.jhsph.edu
This press release was posted to serve as a topic for discussion. Please comment below. We try our best to only post press releases that are associated with peer reviewed scientific literature. Critical discussions of the research are appreciated. If you need help finding a link to the original article, please contact us on twitter or via e-mail.
Surgeons in Australia say they have performed the first heart transplant using a "dead heart".
Ebola underlines the urgent need for a new way of responding to global epidemics, say Harvey Rubin and Nicholas Saidel
As researchers from Africa to China to America race to develop vaccines and treatments to fight Ebola, health experts are grappling with the economics of a disease that until this year had been off the drug industry's radar.
Is California's severe drought hurting the nutrient content of fruit? No, preliminary data on pomegranates suggest. The fruit may be smaller, but packed with more antioxidants, tests show.
The Food and Drug Administration has issued warning letters to companies marketing products claimed to be cures for Ebola. One firm says it will drop such claims — but it's still selling the product.
Parents of baby with fatal mitochondrial disease say techniques being considered by select committee could prevent them having another seriously ill child
Ultrasound has been used to open the brain's protective sheath in people with aggressive brain tumours – to deliver chemo drugs directly to cancer cells
The World Health Organization says two vaccine candidates now undergoing small-scale tests of dosage and safety in people might be ready for broader deployment in Africa by early 2015.
Just because the Food and Drug Administration recalls a supplement because it contains dangerous substances, doesn't mean the product disappears from the market.
9 million new cases and 1.5 million deaths in 2013